Yungjin Pharm. Co., Ltd. (KRX:003520)
2,080.00
+5.00 (0.24%)
Feb 19, 2025, 9:00 AM KST
Yungjin Pharm. Revenue
Yungjin Pharm. had revenue of 38.98B KRW in the quarter ending September 30, 2013, with 4.67% growth. This brings the company's revenue in the last twelve months to 158.79B, up 23.36% year-over-year. In the year 2012, Yungjin Pharm. had annual revenue of 137.69B with 22.82% growth.
Revenue (ttm)
158.79B
Revenue Growth
+23.36%
P/S Ratio
2.09
Revenue / Employee
276.63M
Employees
574
Market Cap
380.42B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2012 | 137.69B | 25.58B | 22.82% |
Dec 31, 2011 | 112.11B | -4.21B | -3.62% |
Dec 31, 2010 | 116.32B | 12.94B | 12.52% |
Dec 31, 2009 | 103.38B | -7.53B | -6.79% |
Dec 31, 2008 | 110.91B | 1.25B | 1.14% |
Dec 31, 2007 | Pro | Pro | Pro |
Dec 31, 2006 | Pro | Pro | Pro |
Dec 31, 2005 | Pro | Pro | Pro |
Dec 31, 2004 | Pro | Pro | Pro |
Dec 31, 1999 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Hanmi Science | 1,283.65B |
Hanall Biopharma | 134.24B |